All In Biotech

Investigational drug · Phase 3

Sefaxersen

Also called: RO7434656

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary IgA Nephropathy.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "Sefaxersen"

First trial start

2023

Aug 8, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Sefaxersen", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Primary IgA Nephropathy

Approved drugs for the same conditions: IgA nephropathy · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Sefaxersen" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Primary IgA Nephropathy

  • TelitaciceptRC18, RC18-LPhase 38 trials

    RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease

  • HRS-5965Phase 36 trials

    Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria

  • NTQ5082Phase 34 trials

    Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy

  • SHR-2173Phase 25 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.